Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of NS-025 in Healthy Subjects
jRCT2031220474Phase 1Completed
- Sponsor
- Nippon Shinyaku
- Start
- Dec 2022
- Countries
- 1
01
Overview
Phase 1, randomised trial of NS-025 (6 arms), sponsored by Nippon Shinyaku. Primary endpoints: Pharmacokinetics, Safety and 1 more. Started Dec 2022; status: completed.
02
Drugs
NS-025
Beyond the preview
Go deeper on jRCT2031220474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220474.